Empower announces partnership with Cannvas Medtech to advance patient education
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
Empower Clinics Inc. is launching a pilot program with Cannvas MedTech to place educational kiosks in each of its clinics to advance the education of patients, collection of data and analysis of physician recommended alternative CBD based therapies.
VANCOUVER, April 18, 2019 /CNW/ - EMPOWER CLINICS INC. (CSE: CBDT) (Frankfurt 8EC) ("Empower" or the "Company"), a growth oriented, diversified health and wellness company, is pleased to announce the signing of a pilot agreement with Cannvas MedTech Inc. ("Cannvas") (CSE: MTEC) (FRA: 3CM) (OTCPK: CANVF), a leading digital cannabis education and analytics company, to launch a comprehensive education, data collection and analysis program starting with the installation of a network of standalone on-site Cannvas Kiosks in the Empower network of medical clinics.
"This is an opportunity to bring unbiased cannabis education to a large population of patients looking for therapies to alleviate a number of ailments while also learning more about what behaviours may drive the decision to look at cannabis as an alternative or complementary treatment," said Shawn Moniz, Chief Executive Officer, Cannvas MedTech. "We are thrilled to partner with Empower Clinics to couple cannabis education with data analysis and better serve their patients while growing the Cannvas brand across the United States."
The partnership installs Cannvas as the exclusive provider of cannabis education to Empower Clinics and its 120,000 patients in the U.S. Cannvas plans to place its Cannvas Kiosks throughout Empower's network of clinics to provide accessible and unbiased cannabis education to its patients, integrating geo-targeting capabilities to ensure relevant contextual information across the country. Cannvas will also be a key data and analytics partner for Empower, providing meaningful insights on customer behaviours and industry trends and integrating mutually beneficial existing data partnerships.
"In recent weeks, the Company has been re-positioning its overall strategy to become a vertically integrated health and wellness company that connects to its 120,000 patients using a data driven focus to improve patients' lives with products, technology and health systems", stated Steven McAuley, Empower CEO, "the addition of the Cannvas educational kiosks, a user friendly and highly interactive education platform, is a tremendous step forward to making our brand the thought leader and go to source for content for both patients and the medical community nationwide."
Every month Empower hosts informational sessions about alternative treatment options and the potential health benefits with doctors and staff available to answer questions. Cannvas expects to play an active role in the review and implementation of new educational curriculum based on original content from Cannvas.Me.
The Company also plans to begin further pilot initiatives with Cannvas to provide content and educational links to Cannvas.me and Cannvas.health directly from the new Empower website www.empowerclinics.com and through the Empower tele-medicine portal.
ABOUT EMPOWER
Empower is a leading owner/operator of a network of physician-staffed clinics focused on helping patients improve and protect their health through innovative physician recommended treatment options. It is expected that Empower's proprietary product line "Sollievo" will offer patients a variety of delivery methods of doctor recommended cannabidiol (CBD) based products in its clinics, online and at major retailers. With over 120,000 patients, an expanding clinic footprint, a focus on new technologies, including tele-medicine, and an expanded product development strategy, Empower is undertaking new growth initiatives to be positioned as a vertically integrated, diverse, market-leading service provider for complex patient requirements in 2019 and beyond.
ABOUT CANNVAS MEDTECH
Cannvas MedTech is a leading digital cannabis education and analytics company delivering accessible and evidence-based education while harnessing the power of data to paint a clearer picture of cannabis consumption across Canada.
For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-6274
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley
Chief Executive Officer
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include statements regarding the Company's proposed name change; new website; and the expected benefits of same for the Company and its stakeholders. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the proposed acquisitions and partnerships, including that: the name change may not be approved by the Company's shareholders or may not be completed; that the website may not operate as expected; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
SOURCE Cannvas MedTech Inc.
Investors: Steve Low, Boom Capital Markets, 647-620-5101; For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-6274; Investors: Steven McAuley, CEO, [email protected], 604-789-2146
Share this article